menu
    • menu
    [{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"B7-H6 Specific CAR T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Celyad Oncology","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Celyad Oncology \/ Fortress Investment Group","highestDevelopmentStatusID":"4","companyTruncated":"Celyad Oncology \/ Fortress Investment Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Celyad Oncology

    Menu

    Celyad Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Celyad Oncology

                            Belgium arrow
                            Antibody Engineering
                            Not Confirmed

                            Celyad Oncology

                            Belgium arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B7-H6 Specific CAR T-cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Fortress Investment Group

                            Deal Size : $10.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Celyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments from Historical Shareholders

                            Details : The proceeds will fund the research and development expenses, to advance its preclinical B7-H6 specific CAR T-cell candidates, to discover and develop additional preclinical product candidates using its proprietary non-gene edited short hairpin RNA techn...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 24, 2023

                            Lead Product(s) : B7-H6 Specific CAR T-cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Fortress Investment Group

                            Deal Size : $10.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth